The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and counting.

IF 2.5 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

American Journal of Managed Care Pub Date : 2024-08-01 DOI:10.37765/ajmc.2024.89590

Julie Patterson, John Michael O'Brien, Jonathan D Campbell

引用次数: 0

Abstract

This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA's accelerated approval program for oncology drugs came to different conclusions.

查看原文本刊更多论文

肿瘤药物加速审批计划：庆祝超过 25 万个生命年的增长。

这篇评论探讨了最近发表的两份研究报告是如何得出不同结论的，这两份研究报告评估了美国食品及药物管理局的肿瘤药物加速审批计划的临床效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Managed Care 医学-卫生保健

CiteScore

3.60

自引率

0.00%

发文量

177

审稿时长

4-8 weeks

期刊介绍： The American Journal of Managed Care is an independent, peer-reviewed publication dedicated to disseminating clinical information to managed care physicians, clinical decision makers, and other healthcare professionals. Its aim is to stimulate scientific communication in the ever-evolving field of managed care. The American Journal of Managed Care addresses a broad range of issues relevant to clinical decision making in a cost-constrained environment and examines the impact of clinical, management, and policy interventions and programs on healthcare and economic outcomes.